20 PARK PLAZA, BOSTON, MA
Market cap: $44.4M (2/10/2026)
Price: $4.80
News
Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Earnings Release
Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Q3
Q2
Q1
FY 2024
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRRN14A
Contested Proxy Solicitation Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
SEC Staff Correspondence
Correspondence